Please login to the form below
RNAi
This page shows the latest RNAi news and features for those working in and with pharma, biotech and healthcare.
Optimum wins Silence Therapeutics account
London, UK-based Optimum Strategic Communications has been appointed by RNAi-focused Silence Therapeutics.
Latest news
-
FDA lifts clinical hold on Sanofi’s haemophilia drug
use to 140, 000 patients in its licensed territories – but particularly for Alnylam which has seen its RNAi platform come under scrutiny in recent months.
-
Boehringer bolsters NASH pipeline with $201m Dicerna deal
Dicerna is a US specialist in RNA interference (RNAi), a technique that switches off messenger RNA associated with specific genes and prevents them from generating their corresponding proteins.
-
Alnylam takes off on APOLLO trial results
APOLLO showed that Alnylam's lead RNAi therapy patisiran is effective as a treatment for the rare disorder hereditary ATTR amyloidosis with polyneuropathy , and critically was well-tolerated by patients, sparking ... the RNAi drug showed significant
-
Alnylam pulls lead drug revusiran after deaths in phase III trial
Shares in the company fell more than 40% yesterday as news of the setback emerged, and Alnylam will now have to concentrate its efforts on patisiran, another RNAi drug in phase
-
Amgen takes aim at cardio diseases with Arrowhead RNAi deal
Amgen takes aim at cardio diseases with Arrowhead RNAi deal. Licenses two gene silencing programmes with up to $670m in the offing for the specialist. ... The other RNAi therapy is for an "undisclosed genetically validated cardiovascular target,"
More from news
Approximately 6 fully matching, plus 33 partially matching documents found.
Latest Intelligence
-
Boosting pharma’s metabolic rate
New frontiers such as cell therapy and RNAi are becoming therapeutic realities and exciting new challenges are coming over the horizon, creating a constantly shifting landscape that leaders must navigate.
-
Deal Watch September 2016
800. Arrowhead / Amgen. Licences. 2 agreements to develop and commercialise RNAi therapies in CVS disease, upfront payments of $35m, $21.5m in equity plus $617m in option payments. ... 95. Geron / J&J. Licence. Exclusive worldwide rights to Geron's
-
Pharma deals during January 2014
Our table includes four RNAi-based deals, so are we seeing a resurgence of interest in this field? ... The deal comprised a range of RNAi assets including pre-clinical candidates, IP and delivery technologies.
-
Deal Watch table for January 2014
300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Bruce Peacock joins Dicerna from Ophthotech
Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
-
Silence appoints chief medical officer
These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
How do you define a biotech company?
This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Senior Medical Writer
-
Great salary and bebefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Senior Account Director, Healthcare Brand Communications, London
-
Excellent Package
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Project Manager, Medical Communications, Oxford
-
Excellent Salary
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Senior Programme Executive
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Scientific Director
-
Great salary and bebefits
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Account Manager – Med Comms – London
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Project Manager, Medical Communications, London
-
Excellent Salary
Subscribe to our email news alerts
No results were found
- P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit
- Publicis LifeBrands Team win UK young Cannes Lions competition
- Sobi poaches Pfizer’s Fredrick Wetterlundh
- Rigel and Ultragenyx claim approvals for rare drugs
- VCCP Health strengthens client service team
- Is agile working benefiting the employee or the organisation?
PMHub
McCann Health
The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...
Latest intelligence
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
- Unique forum will unite NHS and industry to drive innovation
- HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...
Quick links
Infographics
